Results for tag: "Congenital Hyperinsulinism Drug"

Congenital Hyperinsulinism (CHI) is a rare endocrine disorder caused by an overproduction of insulin. It is characterized by persistent hypoglycemia, which can lead to seizures, coma, and even death if left untreated. Treatment for CHI typically involves the use of drugs to reduce the amount of insulin produced by the body. These drugs are known as Congenital Hyperinsulinism Drugs (CHID). CHID are typically used in combination with dietary and lifestyle modifications to reduce the risk of hypoglycemia. Commonly used CHID include diazoxide, octreotide, and somatostatin analogs. These drugs work by blocking the release of insulin from the pancreas, thereby reducing the amount of insulin in the body. CHID are an important part of the endocrine and metabolic disorder drug market. They are used to treat a wide range of endocrine and metabolic disorders, including CHI, diabetes, and obesity. Companies in the CHID market include Novo Nordisk, Sanofi, Eli Lilly, and Merck. Show Less Read more